Oppenheimer analyst Mark Breidenbach reiterated a Perform rating on bluebird bio (NASDAQ: BLUE).The analyst comments "While the company has excelled ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE